Portfolio
Portfolio Companies
The Cancer Focus Fund’s portfolio companies are driven to revolutionize the industry of cancer therapies and provide patients with better outcomes in the process.
Mereo BioPharma (NASDAQ: MREO) is a publicly traded San Diego and London-based biotech developing and commercializing new therapies for oncology and rare disease.
KAHR is a private clinical stage company based in Israel developing innovative immune-recruitment cancer drugs that activate immune responses by converting cancer camouflage into beacons for the immune system to attack.
Nectin Therapeutics is a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology treatments.

Mereo BioPharma (NASDAQ: MREO) is a publicly traded San Diego and London-based biotech developing and commercializing new therapies for oncology and rare disease. The Mereo and Cancer Focus Fund partnership will evaluate Mereo’s lead anti-TIGIT therapeutic antibody candidate, etigilimab, in clear cell ovarian cancer, a rare cancer that accounts for approximately 5-10% of all ovarian carcinomas in North America.
Investment Date
April 30, 2021
Related Press
Mereo and Focus Fund Announce Etigilimab partnership with MD Anderson
Mereo BioPharma | 04/30/21

KAHR is a private clinical stage company based in Israel developing innovative immune-recruitment cancer drugs that activate immune responses by converting cancer camouflage into beacons for the immune system to attack. The Cancer Focus Fund investment will support a Phase 1/2 clinical study assessing KAHR’s first-in-class CD47x41BB targeting agent in the treatment of acute myeloid leukemia, myelodysplastic syndrome and T-cell lymphoproliferative diseases.
Investment Date
May 26, 2021
Related Press
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
PR Newswire | 02/17/2022
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers
PR Newswire | 05/26/2021

Nectin Therapeutics is a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology treatments. The Cancer Focus Fund investment will support a Phase 1 clinical trial of Nectin’s PVR blocker, NTX1088, in cancer patients with locally advanced and metastatic solid tumors.
Investment Date
February 23, 2022